SAN FRANCISCO– Headlamp Health, a digital health company on the forefront of precision psychiatry, today announced the appointment of Erwin Estigarribia as Chief Executive Officer to spearhead the next phase of growth and commercialization for the company. Estigarribia brings more than 25 years of expertise in global business transformation, fundraising, product development and commercialization, and strategic partnerships in the life sciences industry to his new role as CEO of Headlamp.
“Throughout his distinguished career, Erwin has developed a proven track record of success with driving substantial growth and building high-performing teams,” said Tom Chavez, Chairman of the Board, Superset. “Headlamp has reached a pivotal moment to accelerate growth under the leadership of a seasoned expert who can foster innovation and help our amazing team scale and grow. We are excited to welcome Erwin to the team and are confident in his ability to help us realize the company vision.”
Headlamp provides scalable, innovative solutions to address the challenges of the global mental health crisis. Each year, an estimated one in eight adults experiences a mental health condition1, yet millions go without the care they need. Clinicians are overwhelmed by soaring demand, placing immense pressure on an already fragile system. The ripple effects of mental health touch every corner of society and impact families, workplaces, and communities.
Estigarribia joins Headlamp at a time of rapid growth in the mental health technology market, which is projected to reach $20 billion by 20302. This surge reflects a growing awareness that traditional care systems alone cannot meet the rising demand for care. As Headlamp’s CEO, Estigarribia will focus on broadening access for clinicians, patients and researchers to empower them with a more comprehensive and higher-resolution view of mental health.
“Headlamp is uniquely positioned to create a step change in care to improve the lives of the millions that are impacted by a mental health diagnosis,” said Estigarribia. “By removing inefficiencies in the psychiatry space, we can provide patients and clinicians with accurate and actionable data leveraging Artificial Intelligence to create patient-specific solutions. I am honored to have the opportunity to lead this company through its next phase of growth, as it aligns perfectly with my expertise and passion for bringing solutions to patients, clinicians, and researchers.”
Prior to joining Headlamp, Estigarribia served as President and CEO of InterVenn Biosciences, the company responsible for launching the world’s first glycoproteomic-AI test. While serving as Chief Operating Officer at InterVenn, his leadership and vision earned him recognition as one of the Top 25 COOs in Healthcare in 2022 by The Healthcare Technology Report, highlighting his dedication to operational excellence and groundbreaking innovation.
Estigarribia has held executive leadership positions at global companies such as Chiron, Novartis, Geron, Nugen, CardioDX, and Applied Proteomics. He achieved a Bachelor of Engineering in Chemical and Bioprocess Engineering with Honors and Distinction from Swinburne University of Technology in Australia.
